Carlee Moser

机构：Harvard University, Sanofi (United States) · ORCID：0000-0001-5601-9112

发表论文 133 篇 · 总被引 3281 次 · h-index 25

代表论文

• Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2 (2024 · JCI Insight · 被引 15)
• The Choice of Viral Load End Point in Early Phase Trials of COVID-19 Treatments Aiming to Reduce 28-Day Hospitalization and/or Death (2025 · The Journal of Infectious Diseases · 被引 4)
• The federated trials approach; an opportunity for global collaboration in health emergencies (2026 · EClinicalMedicine · 被引 1)
• Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy (2025 · Open Forum Infectious Diseases · 被引 1)
• Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial (2025 · Contemporary Clinical Trials · 被引 1)
• Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies (2025 · iScience · 被引 1)